Hudson Capital Management LLC Makes New $248,000 Investment in Novartis AG $NVS

Hudson Capital Management LLC bought a new position in Novartis AG (NYSE:NVS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,048 shares of the company’s stock, valued at approximately $248,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Essex Savings Bank increased its position in Novartis by 1.9% in the second quarter. Essex Savings Bank now owns 4,611 shares of the company’s stock worth $558,000 after buying an additional 85 shares during the period. Physician Wealth Advisors Inc. increased its position in Novartis by 5.8% in the second quarter. Physician Wealth Advisors Inc. now owns 1,541 shares of the company’s stock worth $186,000 after buying an additional 85 shares during the period. Gallacher Capital Management LLC increased its holdings in shares of Novartis by 1.7% during the second quarter. Gallacher Capital Management LLC now owns 5,371 shares of the company’s stock valued at $650,000 after purchasing an additional 92 shares during the period. Ascent Group LLC increased its holdings in shares of Novartis by 0.7% during the second quarter. Ascent Group LLC now owns 14,121 shares of the company’s stock valued at $1,709,000 after purchasing an additional 97 shares during the period. Finally, Sage Rhino Capital LLC increased its holdings in shares of Novartis by 1.2% during the second quarter. Sage Rhino Capital LLC now owns 8,120 shares of the company’s stock valued at $983,000 after purchasing an additional 99 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NVS. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Novartis in a report on Thursday, August 21st. The Goldman Sachs Group reissued a “sell” rating and set a $118.00 price target (down from $119.00) on shares of Novartis in a report on Friday, September 12th. Morgan Stanley raised Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target on the stock in a report on Friday, August 8th. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Novartis presently has a consensus rating of “Hold” and an average target price of $120.33.

Novartis Price Performance

NYSE:NVS opened at $129.31 on Tuesday. The business’s 50-day moving average price is $125.37 and its 200 day moving average price is $118.07. The firm has a market cap of $273.16 billion, a P/E ratio of 18.82, a PEG ratio of 1.80 and a beta of 0.64. Novartis AG has a 52-week low of $96.06 and a 52-week high of $133.55. The company has a quick ratio of 0.62, a current ratio of 0.82 and a debt-to-equity ratio of 0.53.

Novartis (NYSE:NVS) last released its earnings results on Thursday, July 17th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The firm had revenue of $14.05 billion for the quarter, compared to analyst estimates of $13.94 billion. Novartis had a return on equity of 41.08% and a net margin of 25.64%.Novartis’s revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.97 earnings per share. As a group, sell-side analysts predict that Novartis AG will post 8.45 earnings per share for the current fiscal year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.